A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised ...

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

But does starting Ozempic really throw off birth control? “I'm not aware of any publications that actually report changes in pregnancy rates themselves,” says Jessica Skelley, a pharmacist at Samford ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Pharmaceutical giant Eli Lilly is demonstrating exceptional market performance, propelled by quarterly results that shattered expectations and a multi-billion dollar expansion initiative. The company ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for Metsera ...

Pfizer has filed a second lawsuit against Danish pharmaceutical giant Novo Nordisk, accusing the company of deliberately stalling its $9 billion bid for biotech firm Metsera to hinder competition in ...

The menopausal transition is a pivotal time in women’s health, bringing about profound hormonal, metabolic and physiologic ...